(Q43630489)

25 November 2017

Additive effect of adenovirus-mediated E2F-1 gene transfer and topoisomerase II inhibitors on apoptosis in human osteosarcoma cells (English)

1 reference

25 November 2017

1 reference

5

K M McMasters

1 reference

25 November 2017

H L Yang

1

1 reference

25 November 2017

Y B Dong

series ordinal

2

1 reference

25 November 2017

M J Elliott

series ordinal

3

1 reference

25 November 2017

S L Wong

series ordinal

4

1 reference

25 November 2017

1 April 2001

1 reference

25 November 2017

1 reference

25 November 2017

8

1 reference

25 November 2017

4

1 reference

25 November 2017

241-251

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.cgt.7700301

25 November 2017

0 references

cites work

Osteosarcoma and other tumors of bone

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700301

7 January 2021

On the current management of osteosarcoma. A critical evaluation and a proposal for a modified treatment strategy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700301

7 January 2021

Soft-tissue sarcomas: an update

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700301

7 January 2021

Chemotherapy of advanced soft-tissue sarcomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700301

7 January 2021

Mechanisms of p53 loss in human sarcomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700301

7 January 2021

Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700301

7 January 2021

Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700301

7 January 2021

The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700301

7 January 2021

Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700301

7 January 2021

Mapping of the p53 and mdm-2 interaction domains

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700301

7 January 2021

The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700301

7 January 2021

Mdm2 promotes the rapid degradation of p53

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700301

7 January 2021

Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700301

7 January 2021

Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700301

7 January 2021

Interaction between the retinoblastoma protein and the oncoprotein MDM2

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700301

7 January 2021

Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700301

7 January 2021

The regulation of E2F by pRB-family proteins

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700301

7 January 2021

Oncogenic capacity of the E2F1 gene

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700301

7 January 2021

Multiple members of the E2F transcription factor family are the products of oncogenes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700301

7 January 2021

Regulation of cell proliferation by the E2F transcription factors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700301

7 January 2021

Deregulated expression of E2F1 induces hyperplasia and cooperates with ras in skin tumor development

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700301

7 January 2021

Tumor induction and tissue atrophy in mice lacking E2F-1

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700301

7 January 2021

E2F-1 functions in mice to promote apoptosis and suppress proliferation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700301

7 January 2021

Key roles for E2F1 in signaling p53-dependent apoptosis and in cell division within developing tumors.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700301

7 January 2021

Loss of E2F-1 reduces tumorigenesis and extends the lifespan of Rb1(+/-)mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700301

7 January 2021

Cellular targets for activation by the E2F1 transcription factor include DNA synthesis- and G1/S-regulatory genes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700301

7 January 2021

p53 and E2F-1 cooperate to mediate apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700301

7 January 2021

Deregulated expression of E2F-1 induces S-phase entry and leads to apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700301

7 January 2021

The transcription factor E2F-1 is a downstream target of RB action

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700301

7 January 2021

E2F-1 cooperates with topoisomerase II inhibition and DNA damage to selectively augment p53-independent apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700301

7 January 2021

Edatrexate in patients with soft tissue sarcoma. Activity in malignant fibrous histiocytoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700301

7 January 2021

Adjuvant chemotherapy with doxorubicin in high-grade soft tissue sarcoma: a randomized trial of the Scandinavian Sarcoma Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700301

7 January 2021

Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas. Implications for decision making in the clinic.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700301

7 January 2021

Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC Soft Tissue and Bone Sarcoma Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700301

7 January 2021

VP-16 in advanced soft tissue sarcoma: a phase II study of the EORTC soft tissue and bone sarcoma group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700301

7 January 2021

Percutaneous transluminal in vivo gene transfer by recombinant adenovirus in normal porcine coronary arteries, atherosclerotic arteries, and two models of coronary restenosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700301

7 January 2021

Genetic determinants of p53-induced apoptosis and growth arrest

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700301

7 January 2021

Manipulation of adenovirus vectors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700301

7 January 2021

E2F1 overexpression in quiescent fibroblasts leads to induction of cellular DNA synthesis and apoptosis.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700301

7 January 2021

E2F1-induced apoptosis requires DNA binding but not transactivation and is inhibited by the retinoblastoma protein through direct interaction

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700301

7 January 2021

Adenovirus-mediated E2F-1 gene transfer efficiently induces apoptosis in melanoma cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700301

7 January 2021

Overexpression of E2F-1 in glioma triggers apoptosis and suppresses tumor growth in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700301

7 January 2021

Induction of DNA synthesis and apoptosis are separable functions of E2F-1.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700301

7 January 2021

Topoisomerases II alpha and beta as therapy targets in breast cancer.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700301

7 January 2021

Cyclin A-kinase regulation of E2F-1 DNA binding function underlies suppression of an S phase checkpoint

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700301

7 January 2021

Identification of the MDM2 oncoprotein as a substrate for CPP32-like apoptotic proteases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700301

7 January 2021

A 60 kd MDM2 isoform is produced by caspase cleavage in non-apoptotic tumor cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700301

7 January 2021

Proteolytic cleavage of the mdm2 oncoprotein during apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700301

7 January 2021

E2F-1-induced p53-independent apoptosis in transgenic mice.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700301

7 January 2021

Identifiers

DOI

10.1038/SJ.CGT.7700301

1 reference

Dimensions Publication ID

25 November 2017

0 references

1 reference